Metastases-directed stereotactic body radiotherapy in combination with targeted therapy or immunotherapy: systematic review and consensus recommendations by …
SGC Kroeze, M Pavic, K Stellamans, Y Lievens… - The lancet …, 2023 - thelancet.com
Stereotactic body radiotherapy (SBRT) for patients with metastatic cancer, especially when
characterised by a low tumour burden (ie, oligometastatic disease), receiving targeted …
characterised by a low tumour burden (ie, oligometastatic disease), receiving targeted …
Safety and survival rates associated with ablative stereotactic radiotherapy for patients with oligometastatic cancer: a systematic review and meta-analysis
Importance The oligometastatic paradigm postulates that patients with a limited number of
metastases can be treated with ablative local therapy to each site of disease with curative …
metastases can be treated with ablative local therapy to each site of disease with curative …
[HTML][HTML] ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer☆
Metastatic breast cancer (MBC) is an incurable disease, but survival improvements have
been reported with appropriate therapeutic strategies. 1-8 Systemic therapy is the standard …
been reported with appropriate therapeutic strategies. 1-8 Systemic therapy is the standard …
Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up☆
LE Hendriks, KM Kerr, J Menis, TS Mok… - Annals of …, 2023 - annalsofoncology.org
Diagnosis of tumour type allows prognostication and triage for biomarker testing (see the
Supplementary Material Section 3 and Supplementary Figure S1, available at https://doi …
Supplementary Material Section 3 and Supplementary Figure S1, available at https://doi …
A Phase 2/3 Prospective Multicenter Study of the Diagnostic Accuracy of Prostate Specific Membrane Antigen PET/CT with 18F-DCFPyL in Prostate Cancer Patients …
Purpose: Prostate specific membrane antigen-targeted positron emission tomography/
computerized tomography has the potential to improve the detection and localization of …
computerized tomography has the potential to improve the detection and localization of …
[HTML][HTML] Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document
Y Lievens, M Guckenberger, D Gomez, M Hoyer… - Radiotherapy and …, 2020 - Elsevier
Background Recognizing the rapidly increasing interest and evidence in using metastasis-
directed radiotherapy (MDRT) for oligometastatic disease (OMD), ESTRO and ASTRO …
directed radiotherapy (MDRT) for oligometastatic disease (OMD), ESTRO and ASTRO …
Nanomedicine embraces cancer radio-immunotherapy: mechanism, design, recent advances, and clinical translation
Cancer radio-immunotherapy, integrating external/internal radiation therapy with immuno-
oncology treatments, emerges in the current management of cancer. A growing number of …
oncology treatments, emerges in the current management of cancer. A growing number of …
Understanding breast cancer complexity to improve patient outcomes: the St Gallen international consensus conference for the primary therapy of individuals with …
G Curigliano, HJ Burstein, M Gnant, S Loibl… - Annals of …, 2023 - Elsevier
The 18th St Gallen International Breast Cancer Conference held in March 2023, in Vienna,
Austria, assessed significant new findings for local and systemic therapies for early breast …
Austria, assessed significant new findings for local and systemic therapies for early breast …
[HTML][HTML] The efficacy and safety of metastasis-directed therapy in patients with prostate cancer: a systematic review and meta-analysis of prospective studies
Context Despite the lack of level 1 evidence, metastasis-directed therapy (MDT) is used
widely in the management of metastatic prostate cancer (mPCa) patients. Data are …
widely in the management of metastatic prostate cancer (mPCa) patients. Data are …
Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer …
Background Most patients with metastatic cancer eventually develop resistance to systemic
therapy, with some having limited disease progression (ie, oligoprogression). We aimed to …
therapy, with some having limited disease progression (ie, oligoprogression). We aimed to …